Immunovo BV is a Dutch private biotechnology company, based in ‘s-Hertogenbosch, engaged in the discovery and clinical development of immunotherapeutics in the field of oncology. The key priority for Immunovo is on its proprietary Immune Activation System (IAS) based on combining synthetic peptide antigens with a novel immune stimulant (adjuvant).   IAS has the potential to be a truly disruptive technology in the immunotherapeutic field as crucially there are fewer economic factors in place which restrict access to wider numbers of patients in comparison to currently prescribed drugs.

Immunotherapy is a rapidly emerging field providing promising new therapies for cancer and other presently incurable diseases. A major attraction of this approach is that it sets out to deliver precisely aimed therapies with significantly reduced risk of side effects and discomfort for the patient. Immunotherapy harnesses the immune system either via elimination or arresting the growth of undesired cells (cancer) or controlling diseases caused by normal biochemical processes that have gone out of control (Alzheimer, hypertension, Crohn’s disease, rheumatoid arthritis, osteoporosis, etc).

Company website